Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635672 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Vincerx Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT02635672 is a Phase 1 study that has completed, run by Vincerx Pharma. The registered enrollment target is 110 participants.
The verdict
NCT02635672, a Phase 1 study, has completed, sponsored by Vincerx Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).
Interventions
- DRUG Keytruda
- DRUG VIP152 (BAY 1251152)
- DRUG VIP152 (BAY 1251152) 30 mg
- DRUG VIP152 (BAY 1251152) 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2016-02-10 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02635672
The ClinicalTrials.gov registry entry for NCT02635672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vincerx Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Keytruda is the first listed.
NCT02635672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02635672 about?
NCT02635672 is a clinical study titled "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer". Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).
What is the current status of trial NCT02635672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2016-02-10. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT02635672?
The interventions under investigation include: Keytruda (DRUG), VIP152 (BAY 1251152) (DRUG), VIP152 (BAY 1251152) 30 mg (DRUG), VIP152 (BAY 1251152) 15 mg (DRUG).
Who is sponsoring clinical trial NCT02635672?
This trial is sponsored by Vincerx Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.